Proteomics in graft-versushost disease and graftversus-leukemia - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 472

[82] Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in pa-
tients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplan-
tation. J Clin Invest 2010;120:1479-93.
[83] Rozmus J, Schultz KR. Biomarkers in chronic graft-versus-host disease. Expert Rev He-
matol 2011;4:329-42.
[84] Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and
chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012;18:S116-24.
[85] Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone
marrow transplantation. Blood 1990;75:555-62.
[86] Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lym-
phocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
[87] Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical
littermate dogs given sublethal total body irradiation before and pharmacological im-
munosuppression after marrow transplantation. Blood 1997;89:3048-54.
[88] Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility
antigens for therapy of leukemia. Immunol Cell Biol 2011;89:396-407.
[89] Chapman M, Warren EH 3rd, Wu CJ. Applications of next-generation sequencing to
blood and marrow transplantation. Biol Blood Marrow Transplant 2012;18:S151-60.
[90] Paczesny S, Braun T, Lugt MV, et al. Three biomarker panel at day 7 and 14 can pre-
dict development of grade II-IV acute graft-versus-host disease. ASH Annu Meet Abstr
2010;116:675.
[91] Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hemato-
poietic stem cell transplant recipients: prevention and therapy. Transplant Infect Dis
1999;1:165-78.
[92] Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-
host disease. Int J Hematol 2011;93:578-85.
[93] Liem L, van Houwelingen H, Goulmy E. Serum cytokine levels after HLA-identical bone
marrow transplantation. Transplantation 1998;66:863-71.
[94] Fujimori Y. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease
after allogeneic bone marrow transplantation. Br J Haematol 2000;109:652-7.
[95] Kitko CL, Paczesny S, Yanik G, et al. Plasma elevations of tumor necrosis factor-recep-
tor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity
and overall survival in pediatric patients. Biol Blood Marrow Transplant 2008;14:759-65.

478